F-2(PMP)(2)-TAM-ZETA(3), A NOVEL COMPETITIVE INHIBITOR OF THE BINDING OF ZAP-70 TO THE T-CELL ANTIGEN RECEPTOR, BLOCKS EARLY T-CELL SIGNALING

被引:87
作者
WANGE, RL
ISAKOV, N
BURKE, TR
OTAKA, A
ROLLER, PP
WATTS, JD
AEBERSOLD, R
SAMELSON, LE
机构
[1] NICHHD, CELL BIOL & METAB BRANCH, BETHESDA, MD 20892 USA
[2] NCI, DCT, DTP, MED CHEM LAB, BETHESDA, MD 20892 USA
[3] UNIV BRITISH COLUMBIA, BIOMED RES CTR, VANCOUVER, BC V6T 1Z3, CANADA
关键词
D O I
10.1074/jbc.270.2.944
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Signaling by the T cell antigen receptor (TCR) is mediated by 17-residue tyrosine-based activation motifs (TAM) present in the cytoplasmic tails of the TCR zeta and CD3 chains. TAMs become tyrosine-phosphorylated upon TCR stimulation, creating a high affinity binding site for the tandem SH2 domains of ZAP-70. In permeabilized T cells, the association of TCR and ZAP-70 was inhibited by a protein tyrosine phosphatase (PTPase)resistant TAM peptide analog, in which difluorophosphonomethyl phenylalanyl (F(2)Pmp) residues replaced phosphotyrosine. Inhibition of this association prevented TCR-stimulated tyrosine phosphorylation of ZAP-70 and reduced ZAP-70 kinase activity to basal levels. The reduction in ZAP-70 activity coincided with reduced tyrosine phosphorylation of a number of substrates. Such PTPase-resistant peptides, capable of disrupting SH2 domain-mediated protein-protein interactions, should prove useful in further dissection of multiple signaling pathways and may serve as models for rationally designed chemotherapeutic agents for the treatment of autoimmune and neoplastic disorders.
引用
收藏
页码:944 / 948
页数:5
相关论文
共 43 条
[1]  
BANIYASH M, 1988, J BIOL CHEM, V263, P18225
[2]   MOLECULAR ASSOCIATIONS BETWEEN THE LYMPHOCYTE-T ANTIGEN RECEPTOR COMPLEX AND THE SURFACE ANTIGEN-CD2, ANTIGEN-CD4, OR ANTIGEN-CD8 AND ANTIGEN-CD5 [J].
BEYERS, AD ;
SPRUYT, LL ;
WILLIAMS, AF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (07) :2945-2949
[3]   NEW INTRACELLULAR TARGETS FOR THERAPEUTIC DRUG DESIGN [J].
BRUGGE, JS .
SCIENCE, 1993, 260 (5110) :918-919
[4]   SYNTHESIS OF 4-PHOSPHONO(DIFLUOROMETHYL)-D, L-PHENYLALANINE AND N-BOC AND N-FMOC DERIVATIVES SUITABLY PROTECTED FOR SOLID-PHASE SYNTHESIS OF NONHYDROLYZABLE PHOSPHOTYROSYL PEPTIDE ANALOGS [J].
BURKE, TR ;
SMYTH, MS ;
OTAKA, A ;
ROLLER, PP .
TETRAHEDRON LETTERS, 1993, 34 (26) :4125-4128
[5]   NONHYDROLYZABLE PHOSPHOTYROSYL MIMETICS FOR THE PREPARATION OF PHOSPHATASE-RESISTANT SH2 DOMAIN INHIBITORS [J].
BURKE, TR ;
SMYTH, MS ;
OTAKA, A ;
NOMIZU, M ;
ROLLER, PP ;
WOLF, G ;
CASE, R ;
SHOELSON, SE .
BIOCHEMISTRY, 1994, 33 (21) :6490-6494
[6]  
BURKHARDT AL, 1994, J BIOL CHEM, V269, P23642
[7]   PRODUCT OF VAV PROTOONCOGENE DEFINES A NEW CLASS OF TYROSINE PROTEIN-KINASE SUBSTRATES [J].
BUSTELO, XR ;
LEDBETTER, JA ;
BARBACID, M .
NATURE, 1992, 356 (6364) :68-71
[8]   THE ZETA-CHAIN IS ASSOCIATED WITH A TYROSINE KINASE AND UPON T-CELL ANTIGEN RECEPTOR STIMULATION ASSOCIATES WITH ZAP-70, A 70-KDA TYROSINE PHOSPHOPROTEIN [J].
CHAN, AC ;
IRVING, BA ;
FRASER, JD ;
WEISS, A .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (20) :9166-9170
[9]  
CHAN AC, 1994, J IMMUNOL, V152, P4758
[10]  
CONTI A, 1993, J BIOL CHEM, V268, P783